Emerging Targeted Therapies for Breast Cancer
The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Increased understanding of the molecular events involved in cancer development has led to the identification of a large number of novel targets and, in parallel, to the development of multiple approaches to anticancer therapy. Targeted therapy focuses on specific molecules in the malignant cell signal transduction machinery, including crucial molecules involved in cell invasion, metastasis, apoptosis, cell-cycle control, and tumor-related angiogenesis. In breast cancer, two new targeted agents have recently been approved: lapatinib, directed against the human epidermal growth factor receptor 2 (HER2); and bevacizumab, directed against vascular endothelial growth factor (VEGF). Multiple other targeted agents are under evaluation in clinical trials, including inhibitors of the epidermal growth factor receptor (EGFR), dual EGFR and HER2 inhibitors, other VEGF or VEGF-receptor inhibitors, and agents that alter crucial signaling pathways, such as RAS/MEK/ERK; phosphatidylinositol-3-kinase/Akt/ mammalian target of rapamycin; insulin-like growth factor/insulin-like growth factor receptor; poly (ADP-ribose) polymerase 1; and others. In this review, we present the most promising studies of these new targeted therapies and novel combinations of targeted therapies with traditional cytotoxic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,531
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Takai, Y., Sasaki, T., & Matozaki, T. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.153 · Cited by 2,475
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 2,157
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 735
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
Baselga, J., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 725
Lin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Burris, H. A., Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.584 · Cited by 619
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
KLIJN, J. G. M., BERNS, P. M. J. J., SCHMITZ, P. I. M., & FOEKENS, J. A. (1992) · Endocrine Reviews · doi:10.1210/edrv-13-1-3 · Cited by 597
Breast Cancer–Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells
Isakoff, S. J., Engelman, J. A., Irie, H. Y., Luo, J., Brachmann, S. M., Pearline, R. V., Cantley, L. C., & Brugge, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2612 · Cited by 509
Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 486
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Strumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H.-J., & Schwartz, B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-426 · Cited by 419
Di Leo, A., Gomez, H. L., Aziz, Z., Zvirbule, Z., Bines, J., Arbushites, M. C., Guerrera, S. F., Koehler, M., Oliva, C., Stein, S. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2578 · Cited by 418
Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., & Ewer, M. S. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60896-3 · Cited by 388
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A. J., Danson, S., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R. S., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 385
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
(2007) · New England Journal of Medicine · doi:10.1056/nejmx070016 · Cited by 350
Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W. C., Arbushites, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0590 · Cited by 338
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H.-J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J.-M., Gutierrez, J., Hong, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0951-3 · Cited by 318
Tolcher, A. W., Mita, M., Meropol, N. J., von Mehren, M., Patnaik, A., Padavic, K., Hill, M., Mays, T., McCoy, T., Fox, N. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8898 · Cited by 314
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
Tsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301
Jones, H. E., Goddard, L., Gee, J. M. W., Hiscox, S., Rubini, M., Barrow, D., Knowlden, J. M., Williams, S., Wakeling, A. E., & Nicholson, R. I. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00799 · Cited by 297
van Golen, K. L., Davies, S. J., Wu, Z.-F., Wang, Y., Bucana, C. D., Root, H., Chandrasekharappa, S. C., Strawderman, M. S., Ethier, S. P., & Merajver, S. D. (1999) · PubMed · Cited by 287
Haluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., Yap, T. A., Roberts, M. L., Sharma, A., Gualberto, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1118 · Cited by 270
Zujewski, J., Horak, I. D., Bol, C. J., Woestenborghs, R., Bowden, C., End, D. W., Piotrovsky, V. K., Chiao, J., Belly, R. T., Todd, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.927 · Cited by 264
Anido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 264
Chu, I., Blackwell, K., Chen, S., & Slingerland, J. (2005) · Cancer Research · doi:10.1158/0008-5472.18.65.1 · Cited by 251
Lane, H. A., Wood, J. M., McSheehy, P. M. J., Allegrini, P. R., Boulay, A., Brueggen, J., Littlewood-Evans, A., Maira, S.-M., Martiny-Baron, G., Schnell, C. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2057 · Cited by 249
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3 · Cited by 242
ErbB-3 Predicts Survival in Ovarian Cancer
Tanner, B., Hasenclever, D., Stern, K., Schormann, W., Bezler, M., Hermes, M., Brulport, M., Bauer, A., Schiffer, I. B., Gebhard, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8397 · Cited by 231
Thomas, A. L., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228
Miles, D., Chan, A., Romieu, G., Dirix, L. Y., Cortes, J., Pivot, X., Tomczak, P., Taran, T., Harbeck, N., & Steger, G. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba1011 · Cited by 213
Burstein, H. J., Storniolo, A. M., Franco, S., Forster, J., Stein, S., Rubin, S., Salazar, V. M., & Blackwell, K. L. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm601 · Cited by 203
Johnston, S. R. D., Hickish, T., Ellis, P., Houston, S., Kelland, L., Dowsett, M., Salter, J., Michiels, B., Perez-Ruixo, J. J., Palmer, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.064 · Cited by 200
Miller, K. D., Trigo, J. M., Wheeler, C., Barge, A., Rowbottom, J., Sledge, G., & Baselga, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1923 · Cited by 198
Kiewe, P., Hasmüller, S., Kahlert, S., Heinrigs, M., Rack, B., Marmé, A., Korfel, A., Jäger, M., Lindhofer, H., Sommer, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2436 · Cited by 197
Harris, A. L., Nicholson, S., Richard, J., Sainsbury, C. A. R., Farndon, J., & Wright, C. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90072-1 · Cited by 183
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
Dickler, M. N., Cobleigh, M., Miller, K. D., Klein, P. M., & Winer, E. P. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0055-9 · Cited by 169
CI-1033, a pan-erbB tyrosine kinase inhibitor
SLICHENMYER, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90285-4 · Cited by 165
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., & Burstein, H. J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn759 · Cited by 164
Finn, R. S., Press, M. F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., Williams, L. S., & Di Leo, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1925 · Cited by 164
Fox, S. B., Smith, K., Hollyer, J., Greenall, M., Hastrich, D., & Harris, A. L. (1994) · Breast Cancer Research and Treatment · doi:10.1007/bf00666180 · Cited by 161
Characterization of RhoC Expression in Benign and Malignant Breast Disease
Kleer, C. G., van Golen, K. L., Zhang, Y., Wu, Z.-F., Rubin, M. A., & Merajver, S. D. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64877-8 · Cited by 157
O’Shaughnessy, J., Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Sledge, G. W., Baselga, J. M., Koehler, M. T., Laabs, S., Florance, A. M., & Roychowdhury, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1015 · Cited by 154
Erlichman, C., Hidalgo, M., Boni, J. P., Martins, P., Quinn, S. E., Zacharchuk, C., Amorusi, P., Adjei, A. A., & Rowinsky, E. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8960 · Cited by 148
Growth factor receptor interplay and resistance in cancer
Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D., & Nicholson, R. I. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01275 · Cited by 130
Allen, L. F., Lenehan, P. F., Eiseman, I. A., Elliott, W. L., & Fry, D. J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70122-x · Cited by 127
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A. N. J., Robson, M. E., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M. L., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra501 · Cited by 120
Guix, M., Granja, N. D. M., Meszoely, I. M., Adkins, T. B., Wieman, B. M., Frierson, K. E., Sanchez, V., Sanders, M. E., Grau, A. M., Mayer, I. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.5939 · Cited by 118
Nonendocrine Pathways and Endocrine Resistance
Nicholson, R. I., Hutcheson, I. R., Knowlden, J. M., Jones, H., Harper, M. E., Jordan, N., Hiscox, S., Barrow, D., & Gee, J. M. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031206 · Cited by 117
Campos, S. M., Hamid, O., Seiden, M. V., Oza, A. M., Plante, M., Potkul, R. K., Lenehan, P. F., Kaldjian, E. P., Varterasian, M. L., Jordan, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.091 · Cited by 106
Inhibition of poly(ADP-ribose) polymerase in cancer
Plummer, E. R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.02.004 · Cited by 106
A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer
Modi, S., D’Andrea, G. M., Norton, L., Yao, T. J., Caravelli, J. F., Rosen, P., Hudis, C. A., & Seidman, A. D. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.040 · Cited by 104
Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., & Baselga, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 98
O'Shaughnessy, J., Osborne, C., Pippen, J., Yoffe, M., Patt, D., Monaghan, G., Rocha, C., Ossovskaya, V., Sherman, B., & Bradley, C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.3 · Cited by 95
Brufsky, A. (2011) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2011.10.016 · Cited by 88
Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer
Nemunaitis, J. J., Eiseman, I. A., Cunningham, C. C., Senzer, N. N., Williams, A., Lenehan, P. F., Olson, S. C., Bycott, P. W., Schlicht, M., Zentgraff, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1950 · Cited by 88
Higano, C. S., Yu, E. Y., Whiting, S. H., Gordon, M. S., LoRusso, P. M., Fox, F. E., Katz, T. L., Roecker, J., & Schwartz, J. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3505 · Cited by 80
Calvo, E., Tolcher, A. W., Hammond, L. A., Patnaik, A., de Bono, J. S., Eiseman, I. A., Olson, S. C., Lenehan, P. F., McCreery, H., LoRusso, P., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1187 · Cited by 80
Tolcher, A. W., Rothenberg, M. L., Rodon, J. A., Delbeke, D., Patnaik, A., Nguyen, L. T., Young, F. M., Hwang, Y. J., Haqq, C., & Puzanov, I. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3002 · Cited by 74
Allen, L. F., Lenehan, P. F., Eiseman, I. A., et al. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.34049 · Cited by 71
Sparano, J. A., Moulder, S., Kazi, A., Vahdat, L., Li, T., Pellegrino, C., Munster, P., Malafa, M., Lee, D., Hoschander, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9114 · Cited by 67
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri, T. K. (2008) · PubMed · Cited by 66
Johnston, S. R. D., Семиглазов, В. Ф., Manikhas, G. M., Spaëth, D., Romieu, G., Dodwell, D. J., Wardley, A. M., Neven, P., Bessems, A., Park, Y. C., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9726-1 · Cited by 66
Vogel, C. L., Burris, H. A., Limentani, S. A., Borson, R. A., O’Shaughnessy, J., Vukelja, S. J., Agresta, S., Klencke, B. J., Birkner, M., & Rugo, H. S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.1017 · Cited by 63
Jayson, G. C., Mulatero, C., Ranson, M., Zweit, J., Jackson, A., Broughton, L., Wagstaff, J., Håkansson, L., Groenewegen, G., Lawrance, J., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2004.11.021 · Cited by 54
Twelves, C. J., Trigo, J. M., Jones, R. J., Rosa, F. D., Rakhit, A. K., Fettner, S. H., Wright, T., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.011 · Cited by 51
Beeram, M., Burris, H. A., Modi, S., Birkner, M., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., & Krop, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1028 · Cited by 48
Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
O'Regan, R. M., & Khuri, F. R. (2004) · Endocrine Related Cancer · doi:10.1677/erc.0.0110191 · Cited by 44
Li, T., Christos, P. J., Sparano, J. A., Hershman, D. L., Hoschander, S., O’Brien, K. M., Wright, J. R., & Vahdat, L. T. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn689 · Cited by 36
Simon, G. R., Garrett, C. R., Olson, S. C., Langevin, M., Eiseman, I. A., Mahany, J. J., Williams, C. C., Lush, R. M., DAUD, A. I., Münster, P. N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2379 · Cited by 32
Garland, L. L., Hidalgo, M. M., Mendelson, D. S., Ryan, D. P., Arun, B. K., Lovalvo, J. L., Eiseman, I. A., Olson, S. C., Lenehan, P. F., & Eder, J. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2507 · Cited by 30
Miles, B. J., & Eigl, B. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5077 · Cited by 28
Cristofanilli, M., Schiff, R., Valero, V., Iacona, R. B., Yu, J., Speake, G., Smith, I. E., & Osborne, C. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.1014 · Cited by 14
Self-citationAnnual Zoledronic Acid: Is Less More?
Higano, C. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8146 · Cited by 12
Mom, C. H., Eskens, F. A. L. M., Gietema, J. A., Nooter, K., Jonge, M. J. D., Amelsberg, A., Huisman, H., Stopfer, P., de Vries, E. G. E., & Verweij, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3025 · Cited by 11
Cited by
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Surrogate markers for targeted therapy-based treatment activity and efficacy
Bianchini, G., & Gianni, L. (2011) · JNCI Monographs · doi:10.1093/jncimonographs/lgr024 · Cited by 2
Metadata
- Authors
- Alvarez, R. H., Valero, V., & Hortobagyi, G. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-07-10
- Volume
- 28
- Issue
- 20
- Pages
- 3366-3379
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2093447167
- Cited by
- 185
- References
- 120
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.